Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $749.0K | $14.0M | $1.1M | $15.2M | $24.4M | $26.0M | $7.1M |
| Cost of revenue | $0 | $76.5K | $176.0K | $276.0K | $1.3M | $2.8M | $3.0M | $0 |
| Gross profit | $20.2M | $672.5K | $13.8M | −$18.6M | $13.9M | $21.5M | $23.0M | $0 |
| Gross margin | 100.0% | 89.8% | 98.7% | -1656.3% | 91.2% | 88.5% | 88.4% | 0.0% |
| R&D | $17.9M | $12.8M | $15.0M | $19.7M | $32.7M | $48.9M | $51.0M | $91.0M |
| Operating income | −$11.2M | −$22.6M | −$2.5M | −$111.2M | −$59.0M | −$71.9M | −$67.5M | −$114.4M |
| EBITDA | −$10.3M | −$24.4M | −$2.5M | −$109.1M | −$60.1M | −$65.4M | −$64.6M | −$114.4M |
| Net income | −$10.4M | −$23.3M | −$3.5M | −$110.1M | −$60.5M | −$65.8M | −$63.7M | −$20.6M |
| Net margin | -51.6% | -3106.9% | -24.8% | -9829.5% | -397.7% | -270.0% | -245.1% | -288.3% |
| EPS (diluted) | -2.11 | -4.73 | -0.51 | -12.41 | -2.69 | -2.44 | -2.36 | -0.03 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $15M | $-0.95 | $-1.06–$-0.84 | 2 |
| 2027 | $34M | $-1.20 | $-1.27–$-1.13 | 2 |
| 2028 | $35M | $-1.30 | $-1.30–$-1.30 | 1 |
| 2029 | $14M | $-1.35 | $-1.35–$-1.35 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds AADI.
No tracked institution reports a position in AADI as of their last filing.
| Execution date | Ratio |
|---|---|
| 2007-12-18 | 4.5-for-1 |
| 2005-08-31 | 5-for-4 |
No one on the platform has traded AADI yet.
| $77M |
| — |
| IMDXInsight Molecular Diagnostics Inc. | $5.42 | +0.37% | $145M | — |
| JNCEJounce Therapeutics, Inc. | $1.88 | +0.00% | $99M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.0× sales vs its 22.2× historical median P/S.
Fair value ≈ $22.87 · price $2.05 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.